Safety of Secukinumab from 1 Million Patient-Years of Exposure: Experience from Post-Marketing Setting and Clinical Trials
ConclusionSecukinumab safety profile with increased patient exposure remained favorable. Paradoxical skin reactions were identified in post-marketing monitoring.
Source: Dermatology and Therapy - Category: Dermatology Source Type: research
More News: Allergy & Immunology | Candida | Clinical Trials | Common Cold | Dermatology | Eczema | Fungal Infections | Inflammatory Bowel Disease | Pneumonia | Skin